Wednesday, January 15, 2020 - The U.S. Food and Drug Administration will hold a public meeting regarding the testing methods for asbestos in talc and other cosmetic products February 4, 2020. The meeting will be available by webcast for those unable to attend the Silver Springs, Maryland venue.
The FDA will hold a public meeting, available online, regarding talc and other cosmetic products. The purpose of this public meeting is to obtain and discuss information and scientific data regarding testing methodologies, terminology, and the criteria needed to measure and characterize asbestos and other elongate mineral particles (EMPs) that have been found in some talc and cosmetic consumer products.
Among the topics discussed will be preliminary recommendations by a federal interagency working group to establish uniform terminology and definitions of EMPs, including asbestos, that are currently of concern to health and wellbeing, as well as information regarding methods, criteria, and terminology to be used in the development of standardized testing of asbestos.
The meeting will be held Feb. 4, 2020 in the great room at the FDA White Oaks Campus, 10903 New Hampshire Ave., Building 31, Silver Spring, MD 20993 from 8:30 a.m. until 5 p.m.
If you would like to attend this meeting, either online or in person, please register here. For general questions about the meeting or to request special accommodations due to a disability, contact Denise Hodge at Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr. (HFS-125), College Park, MD 20704. You can also call 301-796-7739 or email firstname.lastname@example.org.
January 17, 2020: Deadline to request special accommodations due to disability
January 17, 2020: Deadline for requests to make an oral presentation
January 28, 2020: Deadline for early registration
February 4, 2020: Public Meeting
March 4, 2020: Deadline to submit electronic or written comments into the docket
OnderLaw, LLC in St. Louis has developed a solid reputation of excellence as a personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation, including Pradaxa, Lexapro and Yasmin/Yaz, Actos, Risperdal and others. The Onder Law Firm has won verdicts of more than $300 million in talcum powder ovarian cancer lawsuits, and has more experience representing Bayer/Monsanto glyphosate cancer victims than any other law firm in the country.